G20 G20.1
Conditions
Interventions
Group 1: This study evaluates the effect of gamma tACS on movement and executive function in Parkinson patients and healthy participants. Both groups undergo 2 sessions: in one session they will recei
Sponsors
Carl von Ossietzky Universität Oldenburg Fakultät VI - Medizin und Gesundheitswissenschaften Department für Humanmedizin
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: Parkinson Patients: a) diagnosed PD in a mild to moderate stage, equivalent UPDRS (part III) < 35 b) Right-handedness c) Age 50 -75 years d) Fluency in German or English. Healthy Subjects are recruited based on : b), c) and d)
Exclusion criteria
Exclusion criteria: For healthy subjects and PD patients: a) Implanted neurostimulators, cochlear implants or general implanted metal in the cranium b) Psychiatric disorders (i.e. schizophrenia, severe dementia) c) Epilepsy d) Use of contraindicated medication (i.e. neuroleptics, opioids) e) Coffee or alcohol consumption prior to the experiment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The endpoint is the improvement of motor function after gamma tACS. Improved motor function will be assessed by the UPDRS, and the UE UPDRS (which is a subscale of the UPDRS targeting the upper extremities) and changes in results of the Nine-hole- peg test and alternating finger tapping task. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is the change in reaction time after the execution of a motor task in the course of the experiment as well as the number of errors in a Go/No-go task. | — |
Countries
Germany
Contacts
Public ContactMartina Bantel
Sekretariat der Universitätsklinik für NeurologieCarl von Ossietzky Universität Oldenburg
Outcome results
None listed